Roche Reports Results of Actemra in P-III EMPACTA Study in Patients with COVID-19 Associated Pneumonia

 Roche Reports Results of Actemra in P-III EMPACTA Study in Patients with COVID-19 Associated Pneumonia

Roche Reports Results of Actemra in P-III EMPACTA Study in Patients with COVID-19 Associated Pneumonia

Shots:

  • The P-III EMPACTA study involves assessing of Actemra + SOC vs PBO + SOC in 389 patients aged > 18yrs. with confirmed SARS-CoV-2 (COVID-19) infection with SpO2 <94% while on ambient air who did not require non/ invasive mechanical ventilation across the US, South Africa, Kenya, Brazil, Mexico, and Peru
  • Results: met its 1EPs i.e. 44% reduction in the likelihood of needing mechanical ventilation, @28days, the cumulative proportion of patients who progressed to mechanical ventilation or death (12.2% vs 19.3%), the incidence of infection (10% vs 11%); the incidence of serious infection (5.0% vs 6.3%) respectively
  • Actemra is the 1st approved anti-IL-6 receptor biologic (both IV and SC) for adult patients with mod. to sev. active RA and is currently being investigated for COVID-19 associated pneumonia, including the P-III REMDACTA trial (in combination with remdesivir)

Click here ­to­ read full press release/ article | Ref: Roche | Image: Roche

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post